FDA Vaccine Chief Vinay Prasad to Depart Agency
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy QURE?
Source: stocktwits
- Departure Sparks Market Reaction: FDA vaccine chief Vinay Prasad is set to leave at the end of April, with shares of Moderna (MRNA) rising 3%, uniQure (QURE) soaring 50%, and Sarepta Therapeutics (SRPT) gaining 5% in after-hours trading, indicating a positive market response to his exit.
- Controversial Tenure: During his time, Prasad faced disputes, notably refusing to consider Moderna's flu vaccine application, although the FDA later reversed its stance after Moderna agreed to conduct a follow-up study, highlighting the complexities of his drug review process.
- FDA Scrutiny on uniQure: The FDA recently recommended that uniQure conduct a sham-surgery-controlled study for its gene therapy targeting Huntington's disease, illustrating the challenges Prasad faced in drug evaluations and the tension with companies affecting their R&D timelines.
- Policy Implementation Completed: Prasad's departure is attributed to the completion of all policies he aimed to implement, including a new priority program to expedite application reviews for treatments meeting national priorities, indicating that his objectives at the FDA have largely been achieved.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 10.650
Low
33.00
Averages
49.88
High
70.00
Current: 10.650
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Vaccine Chief Vinay Prasad to Depart Agency
- Departure Sparks Market Reaction: FDA vaccine chief Vinay Prasad is set to leave at the end of April, with shares of Moderna (MRNA) rising 3%, uniQure (QURE) soaring 50%, and Sarepta Therapeutics (SRPT) gaining 5% in after-hours trading, indicating a positive market response to his exit.
- Controversial Tenure: During his time, Prasad faced disputes, notably refusing to consider Moderna's flu vaccine application, although the FDA later reversed its stance after Moderna agreed to conduct a follow-up study, highlighting the complexities of his drug review process.
- FDA Scrutiny on uniQure: The FDA recently recommended that uniQure conduct a sham-surgery-controlled study for its gene therapy targeting Huntington's disease, illustrating the challenges Prasad faced in drug evaluations and the tension with companies affecting their R&D timelines.
- Policy Implementation Completed: Prasad's departure is attributed to the completion of all policies he aimed to implement, including a new priority program to expedite application reviews for treatments meeting national priorities, indicating that his objectives at the FDA have largely been achieved.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
uniQure Investors Encouraged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to significant losses incurred by investors who purchased securities between September 24 and October 31, 2025, potentially leading to a federal securities class action.
- FDA Approval Issues: The company is accused of failing to disclose that the design of its pivotal study was not fully approved by the FDA, misleading investors about its business prospects and impacting stock performance.
- Stock Price Plummet: On November 3, 2025, uniQure's stock price fell by $33.40, or over 49%, from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data for a BLA submission, indicating severe market concerns.
- Class Action Deadline: Faruqi & Faruqi reminds investors that April 13, 2026, is the deadline to seek the role of lead plaintiff in the class action, urging timely action to protect their rights.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with a deadline of April 13, 2026, for investors to seek lead plaintiff status.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the clinical trial data for AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, severely undermining investor confidence.
- Legal Implications: The lawsuit alleges that uniQure failed to disclose that its clinical trial design was not fully approved by the FDA and that it might need to delay its Biologics License Application (BLA), leading to investor misconceptions about the company's prospects and negatively impacting its market performance.
- Investor Action: Kessler Topaz Meltzer & Check, LLP encourages uniQure investors to contact the firm by April 13, 2026, to discuss options for becoming lead plaintiff or to choose to remain an absent class member without any obligation.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
FDA Vaccine Chief Vinay Prasad to Depart Agency
- Departure Sparks Market Reaction: FDA vaccine chief Vinay Prasad is set to leave at the end of April, with shares of Moderna (MRNA) rising 3%, uniQure (QURE) soaring 50%, and Sarepta Therapeutics (SRPT) gaining 5% in after-hours trading, indicating a positive market response to his exit.
- Controversial Tenure: During his time, Prasad faced disputes, notably refusing to consider Moderna's flu vaccine application, although the FDA later reversed its stance after Moderna agreed to conduct a follow-up study, highlighting the complexities of his drug review process.
- FDA Scrutiny on uniQure: The FDA recently recommended that uniQure conduct a sham-surgery-controlled study for its gene therapy targeting Huntington's disease, illustrating the challenges Prasad faced in drug evaluations and the tension with companies affecting their R&D timelines.
- Policy Implementation Completed: Prasad's departure is attributed to the completion of all policies he aimed to implement, including a new priority program to expedite application reviews for treatments meeting national priorities, indicating that his objectives at the FDA have largely been achieved.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
uniQure Investors Encouraged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to significant losses incurred by investors who purchased securities between September 24 and October 31, 2025, potentially leading to a federal securities class action.
- FDA Approval Issues: The company is accused of failing to disclose that the design of its pivotal study was not fully approved by the FDA, misleading investors about its business prospects and impacting stock performance.
- Stock Price Plummet: On November 3, 2025, uniQure's stock price fell by $33.40, or over 49%, from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data for a BLA submission, indicating severe market concerns.
- Class Action Deadline: Faruqi & Faruqi reminds investors that April 13, 2026, is the deadline to seek the role of lead plaintiff in the class action, urging timely action to protect their rights.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with a deadline of April 13, 2026, for investors to seek lead plaintiff status.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the clinical trial data for AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, severely undermining investor confidence.
- Legal Implications: The lawsuit alleges that uniQure failed to disclose that its clinical trial design was not fully approved by the FDA and that it might need to delay its Biologics License Application (BLA), leading to investor misconceptions about the company's prospects and negatively impacting its market performance.
- Investor Action: Kessler Topaz Meltzer & Check, LLP encourages uniQure investors to contact the firm by April 13, 2026, to discuss options for becoming lead plaintiff or to choose to remain an absent class member without any obligation.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
